<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00600860</url>
  </required_header>
  <id_info>
    <org_study_id>883</org_study_id>
    <nct_id>NCT00600860</nct_id>
  </id_info>
  <brief_title>A Prospective, Multicentre European Registry for Newly Diagnosed Patients With Myelodysplastic Syndromes</brief_title>
  <acronym>EUMDS</acronym>
  <official_title>A Prospective, Multicentre European Registry for Newly Diagnosed Patients With Myelodysplastic Syndromes (MDS), Including Acute Myeloid Leukaemia With 20-&lt;30 Percent Marrow Blasts (Former RAEB-t), and Chronic Myelomonocytic Leukaemia (CMML)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Radboud University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Radboud University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Study Objectives:&#xD;
&#xD;
      To collect and describe demographics, disease-management, and treatment outcomes of&#xD;
      Myelodysplastic Syndromes (MDS) patients who are newly diagnosed and classified according to&#xD;
      the World Health Organization (WHO) criteria.&#xD;
&#xD;
      To perform observational studies concerning relevant scientific research questions in MDS&#xD;
      using clinical data and biological samples, and to present relevant research outcomes in the&#xD;
      fields of diagnosis and prognostication, health related quality of life issues, health&#xD;
      economics, and risk stratification for newly developed classes of drugs.&#xD;
&#xD;
      To disseminate results of the studies to all stakeholders involved.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Methodology:&#xD;
&#xD;
      Data on patients with MDS will be collected prospectively at diagnosis and at 6-months&#xD;
      intervals after diagnosis. The data will be gathered by seventeen (or more) countries that&#xD;
      are represented within the LeukemiaNet MDS Working Party and will be combined in one central&#xD;
      European Database. Data analyses will be conducted by the Data Management Centre at the&#xD;
      University of York in various sub studies, at specific time points as decided or requested by&#xD;
      the steering committee, but at least once a year included in the European Registry and at the&#xD;
      end of the follow-up period.&#xD;
&#xD;
      Number of Patients &amp; Centres Over 149 hematology centres in eighteen (or more) different&#xD;
      countries (Austria, Croatia, Czech Republic, Denmark, France, Germany, Greece, Israel, Italy,&#xD;
      The Netherlands, Romania, Spain, Sweden, Switzerland and United Kingdom) will participate as&#xD;
      referral centres in this Registry. The recruitment target is a minimum of 3000 cases&#xD;
      lower-risk MDS and 1000 higher-risk cases.&#xD;
&#xD;
      Population:&#xD;
&#xD;
      The study population will consist of newly diagnosed patients with all subtypes of MDS&#xD;
      classified according to the WHO criteria, including therapy-related MDS and MDS-F, AML with&#xD;
      20-&lt;30 percent marrow blasts (former RAEB-t), and CMML and other forms of mixed MDS/MPD.&#xD;
&#xD;
      Study Duration:&#xD;
&#xD;
      The enrolment time is scheduled to continue until at least December 2022 but extension of the&#xD;
      recruitment period is possible. Patients will be followed until withdrawal (for any reason)&#xD;
      or termination of the EUMDS Registry.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>April 2008</start_date>
  <completion_date type="Anticipated">June 30, 2023</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2022</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Demographics</measure>
    <time_frame>14.5 years of follow-up (FU)</time_frame>
    <description>The primary objective of this study is collect and describe demographics, clinical and lab manifestations, epidemiological data, genetic characteristics, HRQoL, disease-management, and treatment outcomes of MDS patients who are newly diagnosed and classified according to the WHO-2008 and WHO-2016 criteria</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Correlations</measure>
    <time_frame>14.5 years of FU</time_frame>
    <description>To investigate the relationship between:&#xD;
Clinical characteristics at inclusion and during follow-up&#xD;
Treatments received, including transfusions, and&#xD;
Responses to treatment&#xD;
Overall survival&#xD;
Disease progression&#xD;
General and disease specific HRQoL, and Karnofsky Performance Status&#xD;
Health Economics</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>New prognostic scoring systems</measure>
    <time_frame>14.5 years of FU</time_frame>
    <description>To derive and validate new prognostic scoring systems</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Scientific research in MDS</measure>
    <time_frame>14.5 years of FU</time_frame>
    <description>To perform observational studies concerning relevant scientific research questions in MDS using clinical data and biological samples and to present relevant research outcomes in the fields of diagnosis &amp; prognostication, HRQoL issues, health economics, risk stratification for newly developed classes of drugs.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Dissemination</measure>
    <time_frame>14.5 years of FU</time_frame>
    <description>To disseminate the results of the studies to all stakeholders involved</description>
  </other_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">4000</enrollment>
  <condition>Myelodysplastic Syndromes (MDS)</condition>
  <arm_group>
    <arm_group_label>MDS patients</arm_group_label>
    <description>Patients with MDS according to current WHO criteria and International Prognostic Scoring System (IPSS) classification</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>No interventions</intervention_name>
    <description>Only registration of clinical practice</description>
    <arm_group_label>MDS patients</arm_group_label>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Blood and Bone marrow&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Clinic&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        Patients must meet all of the following criteria&#xD;
&#xD;
          -  Age &gt; 18 years&#xD;
&#xD;
          -  Newly diagnosed patient (within 100 days from the date of the diagnostic bone marrow&#xD;
             (BM) aspirate)&#xD;
&#xD;
          -  MDS classified according to current WHO criteria&#xD;
&#xD;
               -  All sub groups of MDS&#xD;
&#xD;
               -  Therapy-related MDS&#xD;
&#xD;
               -  MDS with Fibrosis (MDS-F)&#xD;
&#xD;
               -  AML with 20-&lt;30 percent marrow blasts (former RAEB-t)&#xD;
&#xD;
               -  CMML and other forms of mixed MDS/MPD&#xD;
&#xD;
          -  IPSS and IPSS-R Risk group classification (mandatory)&#xD;
&#xD;
          -  Able and willing to provide the written informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Age &lt;18 years&#xD;
&#xD;
          -  Patient unwilling or unable to give consent&#xD;
&#xD;
          -  AML with â‰¥30 percent marrow blasts according to WHO&#xD;
&#xD;
          -  Patients with inv(16), t(5;17) and t(8;21) are considered AML and therefore not&#xD;
             eligible&#xD;
&#xD;
          -  Patients with higher risk MDS progressed from a previously diagnosed lower risk MDS&#xD;
             that was not registered within 100 days after first diagnosis of (lower risk) MDS&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>David Bowen, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Leeds General Infirmary</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Theo de Witte, Prof Dr</last_name>
    <role>Study Director</role>
    <affiliation>Radboud University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Corine J van Marrewijk, PhD</last_name>
    <phone>+31-24-3614794</phone>
    <email>corine.vanmarrewijk@radboudumc.nl</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Rosalie Lubbers, MSc</last_name>
    <phone>+31-24-3614794</phone>
    <email>rosalie.lubbers@radboudumc.nl</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University of Innsbruck Fachartz fur Innere Medizin, Dept of Hematology</name>
      <address>
        <city>Innsbruck</city>
        <country>Austria</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Clinical Hospital Merkur</name>
      <address>
        <city>Zagreb</city>
        <country>Croatia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Institute of Haematology and Blood Transfusion U nemocnice</name>
      <address>
        <city>Prague</city>
        <country>Czechia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Aarhus University Hospital</name>
      <address>
        <city>Aarhus</city>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hopital Avicenne Universite Paris, Dept of Hematology</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Medizinische Klinik und Poliklinik fur Haematologie, Onkologie und Klinische Immunologie</name>
      <address>
        <city>Dusseldorf</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>University of Patras Medical School, Haematology Division, Dept of Internal Medicine</name>
      <address>
        <city>Patras</city>
        <country>Greece</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Tel-Aviv Sourasky Medical Center, Dept. of Medicine A</name>
      <address>
        <city>Tel-Aviv</city>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>University of Pavia Medical SChool, Dept of Hematology</name>
      <address>
        <city>Pavia</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Radboud University Nijmegen Medical Centre, dept of Hematology</name>
      <address>
        <city>Nijmegen</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Medical University, Dept of Hematology, Oncology and Internal Medicine</name>
      <address>
        <city>Warszawa</city>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Instituto PortuguÃªs de Oncologia de Lisboa,</name>
      <address>
        <city>Lisbon</city>
        <country>Portugal</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Fundeni CLinical Institute, Clinic of Hematology</name>
      <address>
        <city>Bucharest</city>
        <country>Romania</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Clinical Center of Vojvodina</name>
      <address>
        <city>Novi Sad</city>
        <country>Serbia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital La Fe, Dept of Hematology</name>
      <address>
        <city>Valencia</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Karolinsky Institute Huddinge University Hospital, Dept of Medicine Division HAematology</name>
      <address>
        <city>Stockholm</city>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Inselspital</name>
      <address>
        <city>Bern</city>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Leeds General Infirmary Dept of Hematology</name>
      <address>
        <city>Leeds</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Austria</country>
    <country>Croatia</country>
    <country>Czechia</country>
    <country>Denmark</country>
    <country>France</country>
    <country>Germany</country>
    <country>Greece</country>
    <country>Israel</country>
    <country>Italy</country>
    <country>Netherlands</country>
    <country>Poland</country>
    <country>Portugal</country>
    <country>Romania</country>
    <country>Serbia</country>
    <country>Spain</country>
    <country>Sweden</country>
    <country>Switzerland</country>
    <country>United Kingdom</country>
  </location_countries>
  <removed_countries>
    <country>Czech Republic</country>
  </removed_countries>
  <link>
    <url>http://www.eumds.org</url>
    <description>European MDS Registry</description>
  </link>
  <link>
    <url>https://mds-europe.eu/</url>
    <description>European MDS network platform</description>
  </link>
  <link>
    <url>https://onlinelibrary.wiley.com/doi/full/10.1111/bjh.13450</url>
    <description>Publication (PMID: 25907546): Validation of the revised international prognostic scoring system (IPSS-R) in patients with lower-risk myelodysplastic syndromes: a report from the prospective European LeukaemiaNet MDS (EUMDS) registry</description>
  </link>
  <link>
    <url>https://onlinelibrary.wiley.com/doi/full/10.1111/joim.12579</url>
    <description>Publication (PMID: 27926979): Erythropoiesis-stimulating agents significantly delay the onset of a regular transfusion need in nontransfused patients with lower-risk myelodysplastic syndrome</description>
  </link>
  <link>
    <url>https://link.springer.com/article/10.1007%2Fs00277-017-3009-7</url>
    <description>Publication (PMID: 28526957): Cytomorphology review of 100 newly diagnosed lower-risk MDS patients in the European LeukemiaNet MDS (EUMDS) registry reveals a high inter-observer concordance</description>
  </link>
  <link>
    <url>http://www.haematologica.org/content/103/1/69.long</url>
    <description>Publication (PMID: 29122992): Labile plasma iron levels predict survival in patients with lower-risk myelodysplastic syndromes</description>
  </link>
  <link>
    <url>https://www.sciencedirect.com/science/article/pii/S0145212618300286?via%3Dihub</url>
    <description>Publication (PMID: 29407183): Prognostic impact of a suboptimal number of analyzed metaphases in normal karyotype lower-risk MDS</description>
  </link>
  <link>
    <url>https://www.nature.com/articles/s41375-018-0089-x</url>
    <description>Publication (PMID: 29572506): Health-related quality of life in lower-risk MDS patients compared with age- and sex-matched reference populations: a European LeukemiaNet study</description>
  </link>
  <link>
    <url>https://ashpublications.org/bloodadvances/article/2/16/2079/15929/Early-platelet-count-kinetics-has-prognostic-value</url>
    <description>Publication (PMID: 30126931): Early platelet count kinetics has prognostic value in lower-risk MDS</description>
  </link>
  <link>
    <url>http://www.haematologica.org/content/early/2019/06/05/haematol.2018.212217.long</url>
    <description>Publication (PMID: 31171638): Impact of red blood cell transfusion dose density on progression-free survival in lower-risk myelodysplastic syndromes patients</description>
  </link>
  <link>
    <url>http://www.haematologica.org/content/early/2019/07/05/haematol.2018.212332.long</url>
    <description>Publication (PMID: 31278207): Impact of treatment with iron chelation therapy in patients with lower-risk myelodysplastic syndromes participating in the European MDS registry</description>
  </link>
  <link>
    <url>https://ashpublications.org/bloodadvances/article/2/14/1765/16249/The-use-of-immunosuppressive-therapy-in-MDS</url>
    <description>Publication (PMID: 30037803): The use of immunosuppressive therapy in MDS: clinical outcomes and their predictors in a large international patient cohort</description>
  </link>
  <verification_date>December 2020</verification_date>
  <study_first_submitted>January 14, 2008</study_first_submitted>
  <study_first_submitted_qc>January 24, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 25, 2008</study_first_posted>
  <last_update_submitted>December 28, 2020</last_update_submitted>
  <last_update_submitted_qc>December 28, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">December 30, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>MDS (all IPSS subtypes)</keyword>
  <keyword>Newly diagnosed</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Preleukemia</mesh_term>
    <mesh_term>Myelodysplastic Syndromes</mesh_term>
    <mesh_term>Syndrome</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>The study results (aggregated data) will be published in an academic journal and presented at scientific meetings. We are working on an update of the website: www.eumds.org. EUMDS related activities and results are also shared via www.mds-europe.eu.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

